Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1671 1672
This examiner grants 33% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18253886 | SINGLE-CHAIN ANTIBODY AGAINST FLAVIVIRUS NS1 PROTEIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18355297 | COMPOSITIONS AND METHODS FOR DETECTING HEV NUCLEIC ACID | Non-Final OA | Gen-Probe Incorporated |
| 18251066 | Compositions and Methods for Detecting Influenza A, Influenza B, and SARS-CoV-2 | Non-Final OA | GEN-PROBE INCORPORATED |
| 18000242 | RNA MOLECULES FOR THE TREATMENT OF CANCER | Non-Final OA | ETH ZÜRICH |
| 18274641 | FC-ENHANCED ANTIBODIES FOR PREVENTION AND TREATMENT OF EBOLA VIRUS INFECTION | Non-Final OA | The General Hospital Corporation |
| 18039818 | METHOD FOR PURIFYING VIRUS | Non-Final OA | Oxford University Innovation Limited |
| 17627502 | ANTI-GRP78 ANTIBODIES AND METHOD OF USE THEREOF | Non-Final OA | Washington University |
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | Non-Final OA | Shionogi & Co., Ltd. |
| 17819182 | ENGINEERED ANTI-HER2 BISPECIFIC PROTEINS | Non-Final OA | Denali Therapeutics Inc. |
| 18273430 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | Non-Final OA | BioMarin Pharmaceutical Inc. |
| 18277612 | METHODS OF STRATIFYING AND TREATING CORONAVIRUS INFECTION | Non-Final OA | University of Mississippi Medical Center |
| 18450554 | METHOD FOR INHIBITING ADVENTITIOUS VIRAL INFECTION | Non-Final OA | Allogene Therapeutics, Inc. |
| 16977547 | CARTYRIN COMPOSITIONS AND METHODS FOR USE | Final Rejection | Poseida Therapeutics, Inc. |
| 18264040 | ATTENUATED AFRICAN SWINE FEVER VIRUS AND ITS USE AS A VACCINE | Non-Final OA | AGENCE NATIONALE DE SECURITE SANITAIRE DE L'ALIMENTATION DE L'ENVIRONNEMENT ET DU TRAVAIL |
| 18014874 | RECOMBINANT ADENOVIRUS VACCINE FOR AFRICAN SWINE FEVER AND METHOD FOR CONSTRUCTING SAME | Non-Final OA | JIAXING ANYU BIOTECHNOLOGY CO., LTD |
| 18258861 | MEANS AND METHODS OF PREVENTING, TREATING AND DETECTING INFECTIONS | Non-Final OA | LEOPOLD GMBH |
| 18258376 | USE OF A BIRNAVIRUS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Non-Final OA | Probiogen AG |
| 18445222 | HPV Detection from urine analyte in male, non-binary and transgender patients | Non-Final OA | HAJJAR, BRIAN JOSEPH |
| 18039833 | METHOD FOR PRODUCING VIRUS | Non-Final OA | THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD |
| 18202836 | RSV VACCINES AND METHODS OF ADMINISTERING SAME | Non-Final OA | Meissa Vaccines, Inc. |
| 18319350 | METHODS OF PREPARING GENE THERAPIES | Non-Final OA | BridgeBio Services Inc. |
| 17788987 | ANTI-CDCP1 ANTIBODY | Non-Final OA | CHIOME BIOSCIENCE INC. |
| 17785011 | ANTI-SERUM ALBUMIN ANTIBODIES | Final Rejection | CULLINAN THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy